Armatus Bio is a startup based in the United States, most recent round Seed, 1 tracked investor.
Armatus Bio is a company founded in 2020 headquartered in the United States. Its most recent tracked round is Seed. Brouky records 1 investor associated with the company.
Armatus Bio is a late-preclinical stage biotech innovator developing vectorized RNAi medicines for neuromuscular disorders, focusing on conditions such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease type 1A (CMT1A). The company leverages advanced RNA interference technology delivered via adeno-associated virus (AAV) vectors to silence disease-causing genes.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.